Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Share your knowledge and expertise with your regulatory peers by submitting an in-depth, evidence-based article focusing on key areas and emerging issues in the global regulatory landscape.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
RAPS Euro Convergence brings regulatory peers from the EU and worldwide together in one forum to gain insights and exchange ideas on the region's most pressing issues. Register today to attend 10-12 May 2021.
Registration is now open for RAPS Convergence 2021! Gather with the regulatory community 12-15 September for four days of learning, engagement, and excitement.
With contributions from more than 30 authors from seven countries, the new edition incorporates a global overview of the field and is designed to help you get the most out of your regulatory intelligence endeavors.
Regipedia is an interactive resource created to benefit RAPS members with 24/7 access to more than 2,300 regulatory terms.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 13 August 2014 | By Stewart Eisenhart,
Content provided by Emergo Group, a medical device regulatory affairs and quality assurance consulting firm with offices worldwide.
Emergo Group colleagues in China have provided additional details on recently published changes to the China Food and Drug Administration’s (CFDA) medical device registration process.
CFDA Administrative Order No. 4 covers new and revised requirements for Class I, II and III device registrations in China that will take effect 1 October 2014.
Class I medical device manufacturers will have to submit filings rather than registrations to the CFDA, which could lead to shorter approval times for such devices. Required documentation for Class I filings include:
Once a filing is submitted to the CFDA, officials will conduct a completeness check to see that all required documents have been included, rather than a technical review. Any changes to the filing will require the applicant to submit a modified application to the CFDA.
For Class II and III device registrations, applicants must provide the following documentation to the CFDA:
Chinese regulators plan to complete initial reviews of Class II registrations within 60 working days and for Class III registrations within 90 working days. Those timeframes will not apply, however, in instances where external expert reviews or combination device-drug reviews are necessary.
In cases where CFDA reviewers request additional information for Class II or III applications, applicants have one year to submit that information to regulators. Additional information submitted will be reviewed within 60 working days, and licenses will be issued within 10 working days of technical reviews.
Finally, medical device licenses issued by the CFDA will remain valid for five-year periods instead of four.
Read more about this topic:
New Chinese Medical Device, IVD Regulations Take Effect in October 2014
Chinese Medical Technology Market Primed for 17% Growth According to Citigroup
Tags: Administrative Order No. 4
Regulatory Focus newsletters
All the biggest regulatory news and happenings.